

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wanker *et al.*

Serial No.: Not Yet Assigned

Filed: Herewith

Attorney Docket No.: 05-40345-US

Group Art Unit: Not Yet Assigned

TITLE: DISEASE RELATED PROTEIN
NETWORK

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)(1)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-identified Applicant submits herewith references, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. Form PTO-1449, attached hereto, lists the references of which Applicant is aware, and which may be material to the examination of this application.

While the information cited in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. § 1.56, the filing of these references should not be construed to be an admission that any patent, publication or other information referred to herein is, or is considered to be, either "prior art" for this invention or otherwise material to the patentability of this invention as defined in 37 C.F.R. § 1.56(b).

14P20 Rec'd PCT/PTO 20 DEC 2005

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure

Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

The references contained in this information disclosure statement were first cited in an International Search Report more than three months prior to the filing of this information disclosure statement.

It is believed that this Information Disclosure Statement is being filed within three (3) months of the filing date of the patent application pursuant to 37 C.F.R. § 1.97(b)(1).

While it is believed that no fee is due in connection with this filing, the Commissioner is hereby authorized to charge any payment of fees or credit any over-payment associated with this application to Deposit Account No. 18-0586.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EV 699478532 US
Date of Deposit: December 20, 2005


I hereby certify that this paper and/or fee is being deposited with the United States Postal Service, "EXPRESS MAIL - POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

Cody M. McAtee

(Name of person mailing paper.)


(Signature of person mailing paper.)

Respectfully submitted,



Nanda P.B.A. Kumar
Registration No. 44,853
REED SMITH LLP
2500 One Liberty Place
1650 Market Street
Philadelphia, PA 19103
(215) 241-7970
Attorney for Applicants

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. 05-40345-US	SERIAL NO. Not Yet Assigned 05/15/2001 1669
	APPLICANT: Wanker <i>et al.</i>	
	FILING DATE Herewith	GROUP Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	6,235,879 B1	05/2001	Kalchman et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	BA	WO 03/045990 A2	06/2003	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Zanzoni et al., "MINT: a Molecular INTERaction database", FEBS Letters, Elsevier Publishers, Amsterdam, NL, vol. 513, no. 1, February 20, 2002, pp. 135-140.
CB	Kleiman et al., "Functional Interaction of BRCA1-Associated BARD1 with Polydenylation Factor CstF-50, Science, Washington, D.C., vol. 285, no. 5433, September 3, 1999, pp. 1576-1579.
CC	Thai et al., "Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers", Human Molecular Genetics, vol. 7, no. 2, February 2, 1998, pp. 195-202.
CD	Sittler et al., "SH3GL3 Associates with the Huntingtin Exon 1 Protein and Promotes the Formation of Polyglutamine-Containing Protein Aggregates", Molecular Cell, Cell Press, Cambridge, MA, vol. 2, no. 4, October 1998, pp. 427-436.
CE	Dunah et al., "Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease", Science, vol. 296, no. 5576, June 21, 2002, pp. 2238-2243.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.